Insight into the Bioactivity and Metabolism of Human Glucagon Receptor Antagonists from 3D‐QSAR Analyses

Descriptors, such as logP, the number of hydrogen bond donors, the number of hydrogen bond acceptors, highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) combined with fields of CoMFA and CoMSIA to construct models for hyperglycemia decrease activity and metabolism of human glucagon receptor antagonists. The results reveal that including logP, HOMO and LUMO energies is meaningful for QSAR/QSMR model. The models were validated by using a test set of structural diverse compounds that had not been included in the CoMFA and CoMSIA models. Support Vector Machines (SVM) have been used to select the suitable additional descriptors to construct 3D-QSAR/ QSMR models. A key factor to mention is that activity and metabolism models simultaneously. These in silico ADME models are helpful in making quantitative prediction of inhibitory activities and rates of metabolism before resorting in vitro and in vivo experimentation.

[1]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[2]  M. Johnson,et al.  The regulation of gluconeogenesis in isolated rat liver cells by glucagon, insulin, dibutyryl cyclic adenosine monophosphate, and fatty acids. , 1972, The Journal of biological chemistry.

[3]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[4]  Thorsten Joachims,et al.  Learning to classify text using support vector machines - methods, theory and algorithms , 2002, The Kluwer international series in engineering and computer science.

[5]  Feng Luan,et al.  Diagnosing Breast Cancer Based on Support Vector Machines , 2003, J. Chem. Inf. Comput. Sci..

[6]  Gerrit Schüürmann,et al.  Multilinear Regression and Comparative Molecular Field Analysis (CoMFA) of Azo Dye-Fiber Affinities. 2. Inclusion of Solution-Phase Molecular Orbital Descriptors , 2003, J. Chem. Inf. Comput. Sci..

[7]  A. Kuki,et al.  Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. , 2002, Journal of medicinal chemistry.

[8]  I. Svendsen,et al.  Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits , 1996, Diabetes.

[9]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[10]  R. Carr,et al.  Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. , 1998, Journal of medicinal chemistry.

[11]  A. Tropsha,et al.  Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. , 2003, Journal of medicinal chemistry.

[12]  V. Hruby,et al.  Design and synthesis of conformationally constrained glucagon analogues. , 2000, Journal of medicinal chemistry.

[13]  Ruisheng Zhang,et al.  QSAR Study of Ethyl 2-[(3-Methyl-2, 5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl) pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF-B Mediated Gene Expression Based on Support Vector Machines , 2003, J. Chem. Inf. Comput. Sci..

[14]  J. McGarry,et al.  Regulation of hepatic fatty acid oxidation and ketone body production. , 1980, Annual review of biochemistry.

[15]  Bernhard Schölkopf,et al.  Learning with kernels , 2001 .

[16]  Hongshi Yu,et al.  ADME-Tox in drug discovery: integration of experimental and computational technologies. , 2003, Drug discovery today.

[17]  Tatiana Nikolskaya,et al.  Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach. , 2003, Journal of medicinal chemistry.

[18]  Bernard F. Buxton,et al.  Drug Design by Machine Learning: Support Vector Machines for Pharmaceutical Data Analysis , 2001, Comput. Chem..

[19]  M. Maccoss,et al.  Substituted imidazoles as glucagon receptor antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[20]  Chih-Jen Lin,et al.  A comparison of methods for multiclass support vector machines , 2002, IEEE Trans. Neural Networks.

[21]  G WhittakerP,et al.  共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値 , 1980 .

[22]  V. Hruby,et al.  A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning. , 2001, Journal of medicinal chemistry.

[23]  Miguel Figueroa,et al.  Competitive learning with floating-gate circuits , 2002, IEEE Trans. Neural Networks.

[24]  S. Ekins,et al.  Application of in silico approaches to predicting drug--drug interactions. , 2001, Journal of pharmacological and toxicological methods.

[25]  Matthew Clark,et al.  The Probability of Chance Correlation Using Partial Least Squares (PLS) , 1993 .

[26]  F J Grant,et al.  Expression cloning and signaling properties of the rat glucagon receptor. , 1993, Science.

[27]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[28]  P. Jurs,et al.  Development and use of charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies , 1990 .

[29]  S. Ekins,et al.  Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.

[30]  S. Ekins,et al.  Present and future in vitro approaches for drug metabolism. , 2000, Journal of pharmacological and toxicological methods.

[31]  L. Orci,et al.  THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS , 1975, The Lancet.

[32]  A. Farah.  Glucagon and the circulation. , 1983, Pharmacological reviews.

[33]  Nello Cristianini,et al.  An introduction to Support Vector Machines , 2000 .

[34]  J. Holst,et al.  Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats , 1994, Diabetologia.

[35]  C. Hansch.  Quantitative approach to biochemical structure-activity relationships , 1969 .

[36]  V. Kulkarni,et al.  Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA. , 2003, Journal of medicinal chemistry.

[37]  Ralf Herbrich,et al.  Learning Kernel Classifiers , 2001 .

[38]  R. Czerminski,et al.  Use of Support Vector Machine in Pattern Classification: Application to QSAR Studies , 2001 .

[39]  A. Kuki,et al.  Identification of alkylidene hydrazides as glucagon receptor antagonists. , 2001, Journal of medicinal chemistry.